Story

Cencora Shares Drop After Disclosing Walgreens Business Shift

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20261 min read
Cencora Shares Drop After Disclosing Walgreens Business Shift
Text size
Background

Shares of Cencora (NYSE: COR) declined on Tuesday after the pharmaceutical distributor confirmed a shift in business volume from its major partner, Walgreens, prompting investor concern despite the company maintaining its full-year financial outlook.

The stock fell approximately 4.8% in trading following the disclosure.

Guidance Reaffirmed Amid Volume Shift

In an 8-K filing with the Securities and Exchange Commission, Cencora reaffirmed its fiscal 2026 guidance for adjusted diluted earnings per share, holding it in the range of $17.75 to $17.95. The company stated this forecast already accounted for a recent change in its business with Walgreens.

Cencora disclosed that effective July 1, certain volumes from Walgreens were moved outside of its operations. The company stressed that this change is separate from its primary contract with the pharmacy giant. According to the filing, its prime vendor agreement with Walgreens, which represents the "vast majority of the related business," remains unchanged.

Sample IUX Markets – In-articleAd

Market Reacts to Client News

The company noted that the impact of this volume shift was fully incorporated into the commentary it provided on August 5. The 8-K filing, signed by Chief Financial Officer Eva C. Boratto, was intended to confirm that its financial projections remain on track.

Despite the reassurance, the market reacted negatively to the news of losing any portion of business from a key client. The share price decline suggests investor apprehension about the stability of the Walgreens relationship or the potential for future volume reductions, even if the immediate financial impact is contained within current guidance.

Read next

More on Stocks
Back to latest news

LATEST